- Home
- FTAIN vs VCEL Comparison
FTAIN vs VCEL Comparison
Compare FTAIN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FTAIN
FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
Current Price
Current Price
Company Overview
Basic Information| Metric | FTAIN | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | 580 | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | FTAIN | VCEL |
|---|---|---|
| Price | $25.37 | $36.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | N/A | ★ 612.7K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $152.42 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | N/A | $29.24 |
| 52 Week High | N/A | $63.00 |
Technical Indicators
Market Signals| Indicator | FTAIN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 47.03 |
| Support Level | $25.34 | $35.53 |
| Resistance Level | $25.53 | $38.15 |
| Average True Range (ATR) | 0.10 | 1.26 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 31.78 | 52.69 |
Price Performance
Historical ComparisonAbout FTAIN FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.